D-2914

IN THE UNITED STATES PATENT AND TRADEMARK PATENT

In re application of WOODWARD et al.

Group Art Unit: 1615

Serial No. 09/847,935

Examiner: Fubara, B.

Filed: May 3, 2001

For: COMPOSITIONS HAVING

ENHANCED PHARMACOKINETIC

FROM-STOUT, UXA BUYAN & MULLINS LLP

CHARACTERISTICS

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents in Washington, DC 20231, to fax number 703-305-3592, September 16,2002 on or before

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C.

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed pursuant to 37 CFR 1.97(c) and is accompanied certification as specified in 37 CFR 1.97(e).

CERTIFICATION UNDER 37 CFR 1.97(e)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication (the

BEST AVAILABLE COM

T-502 P 18/99 F-930

D-2914

FROM-STOUT, UXA, BUYAN & MULLINS LLP

International Search Report) from a foreign patent office (The acting as the International European Patent Office) Authority in a counterpart foreign (PCT) patent application no more than three months prior to the filing of this Supplemental Information Disclosure Statement (a copy of the International Search Report is enclosed).

ctfully submitted,

Attorney for Applicant Reg. No. 25,612 4 Venture, Suite 300 Irvine, CA 92618 (949) 450-1750

Facsimile (949) 450-1764

FJUxa/ac